- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Laurus Labs Limited — Board Meeting, 23-01-2026: Outcome of Board Meeting
23-01-2026 | 02:51 pm
23-01-2026 | 02:51 pm
Laurus Labs' Board has approved consolidated financial results for Q3 FY26: Revenue from Operations at ₹1,778.29 Cr and Net Profit at ₹253.11 Cr. Key investments include ₹35 Cr in Laurus Bio and ₹49 Cr for a 49% stake in JV KRKA Pharma. A demerger scheme is pending NCLT approval.
No comments yet. Be the first to comment!